Amrutanjan Health Care Ltd.
Snapshot View

View in App

Prices View details

837.00 +17.75 ▲2.2%

20 May 2022, 04:01:00 PM
Volume: 1,860

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.amrutanjan.com
Market Cap 2,441.34 Cr.
Enterprise Value(EV) 2,366.87 Cr. 2021-09
Financial Indicators
Earnings per share (EPS) 21.45 Trailing Twelve Months Ending 2021-12
Price-Earning Ratio (PE) 38.93 Trailing Twelve Months Ending 2021-12
Industry PE 29.26 Trailing Twelve Months Ending 2021-12
Book Value / Share 88.81 Trailing Twelve Months Ending 2021-12
Price to Book Value 9.40 Calculated using Price: 835.20
Dividend Yield 0.19 Period Ending 2021-03
No. of Shares Subscribed 2.92 Cr. 29,230,630 Shares
FaceValue 1
Company Profile

Amrutanjan Health Care was started in the year 1893 by social reformer, journalist and freedom fighter, Nageswara Rao Pantulu Garu. Today Amrutanjan is one of the household names in South India.

While Amrutanjan Pain Balm (Yellow Balm) is the flagship brand of the company with a rich heritage of over 100 years, the company is also planning to introduce a series of next generation products in healthcare category.

With a wide range of ayurvedic and allopathic products, Amrutanjan has helped millions of people relieve themselves from the pain and discomfort of headaches, colds, sprains, muscular pains, rheumatic pains and stands a real pain management specialist for its loyal customers.

The company has diversified into various businesses in the health care segment like the Fine Chemical Division and Osmosys Medical Clinic located in Chennai.  Apart from the products in the pain care segment, other categories include cough and cold care, health and home care.

Its products are available in the Gulf, African, South East and Asian countries. Plans are ready to enter the US and European markets in a big way.

Products

  • Amrutanjan pain balm
  • Dragon Roll-on liquid balm
  • Joint ache cream
  • Pain relief kit
  • Cold rub
  • Vaporising gel
  • Cough drops
  • Swas mint
  • Diakyur capsules
  • Jiffy tablets
  • Decorn (corn caps)
  • Cutis olive oil, etc.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+2.17%
1 Week
+3.05%
1 Month
-5.90%
3 Month
+5.97%
6 Month
-8.43%
1 Year
+13.77%
2 Year
+149.44%
5 Year
+134.99%
10 Year
+1027.73%

Ratios View Details

9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 14.36 15.72 16.97 19.90 18.46 16.41 17.87 16.44 32.69
Return on Capital Employed (%) 19.90 22.63 26.06 30.86 28.65 26.95 25.43 22.80 44.00
Return on Assets (%) 9.67 11.58 13.45 16.07 14.66 12.89 14.18 13.05 25.94

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-09* Rs. Cr.
Shh. Funds 88 97 105 120 116 129 146 159 216 239
Non Curr. Liab. 3 3 2 3 1 1 2 2 3 3
Curr. Liab. 35 24 23 25 32 32 36 39 52 65
Minority Int.
Equity & Liab. 127 124 130 149 149 162 183 201 271 307
Non Curr. Assets 69 51 52 54 41 41 44 75 47 56
Curr. Assets 58 73 79 95 108 121 140 126 224 250
Misc. Exp. not W/O
Total Assets 127 124 130 149 149 162 183 201 271 307

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-12 Rs. Cr. TTM
Net Sales 135 139 163 184 212 220 253 261 333 393
Other Income 4 4 5 6 7 8 7 8 11 13
Total Income 139 143 168 190 219 228 261 270 344 406
Total Expenditure -116 -116 -139 -153 -182 -192 -222 -231 -258 -318
PBIDT 24 26 29 37 37 36 38 39 86 88
Interest -2 -2 -1 0 -1 0 0 0 -1 -1
Depreciation -3 -3 -2 -3 -3 -3 -3 -4 -4 -4
Taxation -6 -7 -9 -12 -12 -13 -10 -9 -21 -22
Exceptional Items
PAT 12 15 17 22 22 20 25 25 61 63
Adjusted EPS 4 5 6 8 7 7 8 9 21 21

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 13 8 18 19 21 8 19 21 18 90
Cash Fr. Inv. 4 11 16 -5 1 0 -8 -11 -14 -88
Cash Fr. Finan. -27 -17 -14 -12 -11 -5 -9 -7 -12 -6
Net Change -9 2 20 2 12 3 2 3 -7 -4
Cash & Cash Eqvt 15 9 29 31 42 25 11 15 7 3

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 50.02 50.02 50.02 50.02 50.02 50.02 50.02 50.02 50.02
Public 49.98 49.98 49.98 49.98 49.98 49.98 49.98 49.98 49.98
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Tue, 17 May 2022
Board to consider Final Dividend
Amrutanjan Health Care Ltd has informed BSE that a meeting of the Board of Directors is scheduled to be held on May 24 2022 thru video Conferencing to consider and approve inter-alia :

1. Audited Financial Results along with the Audit Report by the statutory Auditors for the quarter and year ended March 31 2022.

2. Declaration of Final Dividend for the financial year 2021-22; if any.

Further as already informed vide the Companys letter dt. March 30 2022 the Trading window for dealing in equity shares of the company is closed effective from April 01 2022 and will remain closed till May 26 2022 pursuant to SEBI (PIT) Regulations 2015 and in terms of Code of Conduct to regulate monitor and report trading in securities of the Company.
Tue, 17 May 2022
Board Meeting Intimation for Intimation Under Regulation Zg(L) Of Sebi (Listing Obligations Requirements) & Disclosure Regulations 201S (SEBI IODR)
AMRUTANJAN HEALTH CARE LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/05/2022 inter alia to consider and approve Pursuant to the above mentioned regulation of SEBI LODR we wish to inform that a meeting of the Board of Directors is scheduled to be held on Tuesday the 24th May 2022 thru videoConferencing to consider and approve inter-alia (i) Audited Financial Results along with the Audit Report by the statutory Auditors for the quarter and year ended March 3I 2022.(ii)Declaration of Final Dividend for the financial year 2021-22; if anyIt may also be noted that as already informed vide our letter dt. 30tÌ March 2022 the Tradingwindow for dealing in equity shares of the company is closed effective from 1st April 2022 and will remain closed till 26tr May 2022 pursuant to SEBI (PIT) Regulations 2015 and in terms of Code of Conduct to regulate monitor and report trading in securities of the Company.Request to take the above on record and acknowledge.
Mon, 16 May 2022
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Dr Pasumarthi Sathyanarayana Murthi

Technical Scans View Details

Fri, 20 May 2022
High Delivery Percentage High Delivery Percentage
Higher Delivery Quantity Higher Delivery Quantity
Higher Delivery Quantity and Percentage Higher Delivery Quantity and Percentage
Closing Above Previous High Closing Above Previous High
High Decrease 1 Month High Decrease 1 Month

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 219,659.12 915.50 +3.5%
Divi's Laboratories Ltd. 114,020.08 4,295.05 +2.2%
Cipla Ltd. 78,954.82 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. 70,669.41 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. 52,783.35 3,671.00 +1.0%
Gland Pharma Ltd. 50,388.39 3,061.70 -1.1%
Piramal Enterprises Ltd. 45,754.22 1,917.10 +1.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 34.09 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 44.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 31.37 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 32.38 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 46.57 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 41.59 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 36.83 1,917.10 +1.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.25 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 10.53 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 3.79 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.68 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.54 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 7.04 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 1.29 1,917.10 +1.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 0.10 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 0.00 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 1,917.10 +1.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 996.96 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 1,917.10 +1.2%